Takeda Pharmaceutical Company Limited (TAK +1.3%) inks an agreement with ProThera Biologics aimed at developing the latter’s plasma-derived Inter-alpha Inhibitor Proteins (IAIP) therapy for acute inflammatory conditions.
The parties will work together on IND-enabling
efforts (preliminary work before the start of clinical trials) with
Takeda leading.
Takeda will be responsible for funding all development and commercialization activities.
Specific financial terms are not disclosed.
https://seekingalpha.com/news/3563688-takeda-teams-up-prothera-in-inflammation
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.